# Add One-Hundred-Thirty-Second Wave Intracellular Quality Control Molecular Maintenance Domains

Date: 2026-07-01

Status: Accepted

## Context

Human Infra already has broad molecular-maintenance domains such as `proteostasis-autophagy/`, `genomic-stability-dna-repair/`, `mitochondrial-bioenergetics/`, `cellular-senescence-clearance/`, and `extracellular-matrix-glycation/`. The latest research-domain scan shows that broad protein homeostasis is too coarse for several first-principles continuity conditions:

- cells must keep terminal recycling and lysosomal waste handling available;
- damaged or misfolded proteins must be selectively marked and degraded;
- newly synthesized proteins must be translated with tolerable fidelity;
- RNA splicing, modification, and mRNA quality control must keep expression programs executable;
- the nucleus must preserve controlled import/export and structural boundary integrity;
- membrane lipid damage and iron-dependent death pathways must not become uncontrolled failure amplifiers.

These conditions are not clinical recommendations. They are lower-level variables for subject-continuity modeling: clearance capacity, protein turnover, translation fidelity, RNA information maintenance, nuclear gateway stability, and membrane-resilience failure.

## Decision

Create six new formal research domains:

- `domains/lysosomal-flux-lipofuscin-clearance-continuity/`
- `domains/ubiquitin-proteasome-protein-turnover-continuity/`
- `domains/ribosome-translation-fidelity-proteome-integrity-continuity/`
- `domains/rna-splicing-epitranscriptomic-maintenance-continuity/`
- `domains/nuclear-gateway-nucleocytoplasmic-transport-continuity/`
- `domains/ferroptosis-lipid-peroxidation-membrane-resilience-continuity/`

Each domain receives a `README.md` and `AGENTS.md`, and the wave is indexed in root docs, `domains/`, `docs/`, reference maps, safety boundaries, `CHANGELOG.md`, and `tools/check_repository.py`.

## Consequences

- `proteostasis-autophagy/` remains the broad upstream bucket for protein folding, aggregation, autophagy, and cell quality control.
- The new domains separate downstream mechanism layers that can each collect evidence without collapsing into a single “anti-aging pathway” narrative.
- Future work can add source cards, variable cards, and model contracts for each mechanism without producing individual intervention guidance.

## Non-Goals

- Do not provide autophagy activation, proteasome modulation, mTOR/ISR adjustment, RNA or gene therapy, nuclear-mechanics intervention, ferroptosis induction/inhibition, supplement, drug, testing, or clinical advice.
- Do not promote animal, cell, or mechanistic signals into human longevity claims.
- Do not treat these domains as proof that effective immortality is currently feasible.

## Source Signals

- PubMed / PMC source scan on lysosomes in senescence and aging, lipofuscin and aging, ubiquitin-proteasome protein turnover, protein synthesis and quality control, translational control and fidelity, RNA imbalance, alternative splicing in aging, mRNA quality control, nuclear gateway / karyopherin aging, and ferroptosis / lipid peroxidation reviews.
- These sources justify domain separation as research-map structure only; they do not provide individual health recommendations.
